1. Home
  2. BZAIW vs WGSWW Comparison

BZAIW vs WGSWW Comparison

Compare BZAIW & WGSWW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blaize Holdings Inc. Warrants

BZAIW

Blaize Holdings Inc. Warrants

N/A

Current Price

$0.31

Market Cap

0.0

Sector

N/A

ML Signal

N/A

Logo GeneDx Holdings Corp.

WGSWW

GeneDx Holdings Corp.

N/A

Current Price

$0.01

Market Cap

0.0

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
BZAIW
WGSWW
Founded
2010
2017
Country
United States
United States
Employees
232
1300
Industry
Retail: Computer Software & Peripheral Equipment
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
N/A
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BZAIW
WGSWW
Price
$0.31
$0.01
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
20.8K
65.9K
Earning Date
05-14-2025
02-18-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,967,000.00
$305,450,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
50.79
52 Week Low
$0.15
$0.01
52 Week High
$1.50
$0.29

Technical Indicators

Market Signals
Indicator
BZAIW
WGSWW
Relative Strength Index (RSI) 46.28 34.52
Support Level $0.20 $0.01
Resistance Level $0.33 $0.02
Average True Range (ATR) 0.06 0.00
MACD 0.00 0.00
Stochastic Oscillator 50.80 9.68

Price Performance

Historical Comparison
BZAIW
WGSWW

About BZAIW Blaize Holdings Inc. Warrants

Blaize Holdings Inc provides a customized, programmable processor architecture suite, artificial intelligence (AI)-enabled edge computing solutions. The company is a semiconductor and software technology company dedicated to revolutionizing the world of AI.

About WGSWW GeneDx Holdings Corp.

GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.

Share on Social Networks: